HAW PAR HEALTHCARE LTD: Labor Productivity Benchmarks and International Gap Analysis (Labor Productivity Series) [Icon Group, Ltd.] on Amazon.com. However, your product does not meet these requirements for the reason described below. Includes a proposed special dividend of 85 cents per share. Haw Par Healthcare Ltd. manufactures Tiger Balm, a renowned ointment, is used worldwide to invigorate the body as well as to relieve aches and pains. Wintergreen oil is also known as methyl salicylate, and “TIGER BALM LINIMENT” contains methyl salicylate 28%. Its largest customer is Prince of Peace Enterprises INC (ca) with most shipments via the port of New York/ … Specify actions that you will. PRINCIPAL DISPLAY PANEL - 57 ml Bottle Box. Sector / Industry Group / Industry: Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals HAW PAR CORP LTD (H02.SI) General HAW PAR CORP LTD (H02.SI) Share Price For more information about handling failing, out-of-specification, out-of-trend, or other unexpected results and documentation of your investigations, see FDA’s guidance document Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production at https://www.fda.gov/media/71001/download. Over the decades, the Group has been disciplined in asset rationalisation, organically growing its core businesses, and making selected acquisitions. The labeler has 13 products that have an assigned National Drug Code. GET IN TOUCH! Haw Par Healthcare Limited. Haw Par Healthcare Limited 401 Commonwealth Drive #03-03 Haw Par Technocentre Singapore 149598 Tel: (65) 6337 9102 Fax: (65) 6262 3436 For enquiries, please email us at tigerbalm@hph.hawpar.com To find out more about Haw Par … The supplier recommended performing additional processing steps before use in manufacturing. Haw Par Healthcare Ltd. labeler's code is 66761. Your detailed CAPA plan to remediate data recording and record retention practices throughout your operation. 320-19-37 dated August 14, 2019). system validation protocol and report and a summary of improvements made to your, Your current procedures for routine monitoring of the redesigned, system as well as system controls and maintenance. PRINCIPAL DISPLAY PANEL - 57 ml Bottle Box. Haw Par Corporation Limited is a Singapore-based company involved in healthcare, leisure products, property and investment.It is the company responsible for Tiger Balm branded liniment (ointment). Haw Par Corporation Limited is engaged in manufacturing, marketing and trading healthcare products; providing leisure-related goods and services, and investing in properties and securities. Its brands also included Kwan Loong and it also owns and operates weekend and leisure time destinations such as oceanariums. Headquartered in Singapore, the Group’s core healthcare and leisure businesses promote healthy Today, the Haw Par Group is an enterprise with a strong consumer healthcare business that promotes healthy lifestyles through its healthcare products. HAW PAR HEALTHCARE LIMITED (the "Company") is a Public Company Limited by Shares, incorporated on 3 June 1988 (Friday) in Singapore. This should include, but not be limited to, test methods, appropriate microbial limits (total count, objectionable organisms), and. 4. TIGER BALM PAIN RELIEVING HYDROGEL- camphor (synthetic), levomenthol, and capsicum patch Haw Par Healthcare Ltd. Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they … Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. In addition, your practice of flushing the system at the manufacturing sampling points before sample collection for (b)(4) analysis is not consistent with how you use these (b)(4) points of use in production. #03-03 Haw Par Technocentre Haw Par Healthcare Ltd. manufactures Tiger Balm, a renowned ointment, is used worldwide to invigorate the body as well as to relieve aches and pains. Haw Par Healthcare Limited 401 Commonwealth Drive #03-03 Haw Par Technocentre Singapore 149598 Tel: (65) 6337 9102 Fax: (65) 6262 3436 For enquiries, please email us at tigerbalm@hph.hawpar.com To find out more about Haw Par Corporation, click here Your firm completed forced degradation studies for your OTC drug products but did not use the data to scientifically establish stability acceptance criteria. suitable for the intended uses of each of your drug products. Co.Registration No: 198801793M: No employees: 100-249 Employees: Kompass ID? 352(f)(2). See FDA’s guidance document. Under the same authority, articles may be subject to refusal of admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act (21 U.S.C. You have not provided an adequate investigation of the additional mixing parameters required for your API to achieve homogeneity. HAW PAR MANAGEMENT SERVICES PTE LTD 401 Commonwealth Drive #03-03, Haw Par Technocentre Singapore 149598 (We regret only shortlisted candidates will be notified) Personal Data Collection [For Job Applications] View Haw Par Healthcare Ltd profile, products & services and other information. You invalidated out-of-specification (OOS) test results for assay for, During your initial investigation you determined adequate raw material mixing had not occurred. 1 - Accession Number 0000013075-98-000019 - Filing - SEC well-known ointment brand in the world. Manufactured by Haw Par Healthcare Ltd., Singapore under licence from Haw Par Corporation Ltd. Describe all parts of your facility’s operations in which CGMP information is not recorded and maintained. Your response is inadequate because you have not provided an interim plan of action to ensure that the products released to the market are of appropriate purity. Haw Par Corporation Limited is a Singapore-based company involved in healthcare, leisure products, property and investment. Our strategic long-term investment portfolio provides a solid foundation that constantly keeps the Group financially buoyant. analysis frequency and locations of sampling points. You also provided sampling data on one batch of (b)(4) from two containers as evidence that your mixing process can achieve homogeneity. Sector / Industry Group / Industry: Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals HAW PAR CORP LTD (H02.SI) General HAW PAR CORP LTD (H02.SI) Share Price Over the decades, the Group has been disciplined in asset rationalisation, organically growing its core businesses, and making selected acquisitions. You also invalidated an assay OOS result for (b)(4), a (b)(4) active ingredient, in (b)(4) Patch without adequately investigating the root cause and released the drug product for distribution. Find the latest Haw Par (H02.SI) stock quote, history, news and other vital information to help you with your stock trading and investing. Your CAPA plan should also include, but not be limited to, improvements in investigation competencies, root cause analysis, written procedures, quality unit oversight, and a process for evaluating CAPA effectiveness. Please tell us the reason for your enquiry * ... Subject Matter * Product related Business related Other MARKETING EXECUTIVE – Haw Par Healthcare Ltd (May2018 – Present) Assist in the planning and formulating of Brand’s (Tiger Balm & Kwan Loong) long-term strategy and developing and executing marketing plans in alignment with Brand Strategic directions. Please tell us the reason for your enquiry * ... Subject Matter * Product related Business related Other HAW PAR HEALTHCARE LTD: Labor Productivity Benchmarks and International Gap Analysis (Labor Productivity Series) [Icon Group, Ltd.] on Amazon.com. Information Request Should you require more information and constant new feeds about Haw Par, we provide an array of convenient access and services for our shareholders. Specify what you have done since our inspection to correct your violations and to prevent their recurrence. Manufactured by Haw Par Healthcare Ltd., Singapore under licence from Haw Par Corporation Ltd. The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. Haw Par Healthcare at 401 COMMONWEALTH DRIVE, #03-03 HAW PAR TECHNOCENTRE, SINGAPORE 149598. 352(f)(2), because the product label fails to include a warning required under 21 CFR 201.303(b). See 21 CFR, parts 210 and 211. The computer systems you use to control the operations of your analytical instrumentation do not have audit trail capabilities, including Gas Chromatography (GC) instruments used for drug product stability analyses and Fourier Transform Infrared Spectroscopy (FTIR) and Ultraviolet (UV) spectroscopy instruments used for raw material release testing. Your firm failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.63). 149598 1. 381(a)(3)). Address: 401 COMMONWEALTH DRIVE 03-03 HAW PAR TECHNOCENTRE SINGAPORE SG Get the inside scoop on jobs, salaries, top office locations, and CEO insights. Even though all sub lots of drug product were made using API from a deficient mixing process, you only rejected portions of the drug product batches that were found to be OOS. The Haw Par Group is an enterprise with a strong consumer healthcare business that promotes healthy lifestyles through its healthcare products. 3. Its brands also included Kwan Loong and it also owns and operates weekend and leisure time destinations such as oceanariums. NDC 66761-308-25. Sector / Industry Group / Industry: Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals HAW PAR CORP LTD (H02.SI) General HAW PAR CORP LTD (H02.SI) Share Price Your response is inadequate because you did not provide sufficient details of how you plan to ensure the integrity of the electronic data you generate until implementation of your updated instrumentation controls. As required in 201.303(b), the labeling must specifically warn that use otherwise than as directed therein may be dangerous and that the article should be kept out of reach of children to prevent accidental poisoning. Manufactured by Haw Par Healthcare Ltd., Singapore under licence from Haw Par Corporation Ltd. You did not establish associated specifications or monitor your drug products for potential impurities or degradation products you identified during your degradation studies. Provide a risk assessment summarizing the effect of incomplete data on assessing laboratory results and product quality. A comprehensive independent review of your entire data system and investigation into the inadequacies in data, records, and reporting. Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. Haw Par Healthcare at 401 COMMONWEALTH DRIVE, #03-03 HAW PAR TECHNOCENTRE, SINGAPORE 149598. Moreover, for the same drug product, you did not adequately investigate a customer complaint reported for a lack of drug effect. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion. In your response, you stated that you have re-designed your (b)(4) circulation line. Today, the Haw Par … *FREE* shipping on qualifying offers. Haw Par Corporation Limited, a Singapore-grown multinational Group, See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at https://www.fda.gov/media/119267/download. You invalidated out-of-specification (OOS) test results for assay for (b)(4), active pharmaceutical ingredient (API) (batches (b)(4) and (b)(4)) without scientific justification. Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov or mail your reply to: Please identify your response with FEI No. sampling points, with consistent sampling procedures, used for manufacturing to ensure that your microbial results comply with specifications. Your studies demonstrating that your analytical test methods, established to monitor impurities in each finished drug product manufactured for the U.S. market are stability indicating. “TIGER BALM LINIMENT” is a “drug” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. Until you correct all violations completely and we confirm your compliance with CGMP, FDA may withhold approval of any new applications or supplements listing your firm as a drug manufacturer. Second, it holds strategic investments where it … Manufactured by Haw Par Healthcare Ltd., Singapore under license from Haw Par Corporation Ltd. Please download the free Adobe Acrobat Reader to view these documents. NDC 66761-333-22. HAW PAR HEALTHCARE LTD… *FREE* shipping on qualifying offers. HAW PAR HEALTHCARE LIMITED is a supplier in Singapore, Singapore. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Your approach to demonstrate that your manufacturing process is validated should be scientifically based. SG004383: Presentation - Haw Par Healthcare Limited. During our inspection, our investigator observed specific violations including, but not limited to, the following. Today, the Haw Par Group is an enterprise with a strong consumer take in response to the risk assessment, such as customer notifications and product recalls. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. Nature: Head Office: Year established: 1988: Describe your Company and attract Business opportunities: See the Kompass classification. Haw Par Healthcare Limited is engaged in manufacturing, supply and distribution of Pharmaceutical products. Find their customers, contact information, and details on 892 shipments. Your acceptance criteria and study design should be scientifically justified. During your initial investigation you determined adequate raw material mixing had not occurred. Senior Vice President, General Counsel and Secretary . Violations cited in this letter are not intended as an all-inclusive list. We believe that one should have compassion for the underprivileged and give back to the community of which one is a part. My Account; My Wishlist; Log In In the interim you will initiate a program to protect raw data from deletion. GET IN TOUCH! … Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. The CAPA should include, but not be limited to, enhanced investigation competencies, improved procedures, and substantial improvements in quality unit oversight of investigations. For investigations that conclusively establish laboratory root cause, determine adequacy of the corrective and preventive action (CAPA), and ensure that other laboratory methods vulnerable to the same root cause are identified for remediation. Trang web này không phải là một thay thế cho các tư vấn y tế. An independent assessment of all test methods and data review procedures used by your firm to ensure they have appropriate instructions, method suitability criteria, and validation to determine whether they are fit for intended purposes. Batch (b)(4) of this API was subsequently used to manufacture multiple batches of your (b)(4) Patch over-the-counter (OTC) drug product. Report Adverse Events, … Our oceanarium showcases the biodiversity and richness of our waters, providing fun and learning for all. 351(a)(2)(B)). We reviewed your March 22, 2019, response in detail and acknowledge receipt of your subsequent correspondence. Your CAPA plan should include, but not be limited to, appropriate controls to maintain and prevent the deletion and alteration of raw data files. A retrospective review of all invalidated OOS (in-process and release testing for raw materials and finished drug products) results obtained for products on the U.S. market and within expiry/retest date. This inconsistent sampling practice could potentially lead to inaccurate microbial results for (b)(4) analysis. In addition, your firm manufactures “TIGER BALM LINIMENT.” The product is misbranded under section 502(f)(2) of the FD&C Act, 21 U.S.C. Several batches of OTC drug product made from these OOS API lots also had OOS results for (b)(4) assay. Manufactured by Haw Par Healthcare Ltd., Singapore under license from Haw Par Corporation Ltd. With a unique herbal formulation that has over 100 years of proven success in 100 countries, Tiger Balm's world renowned ointment is arguably the world's leading and most versatile topical analgesic brand. Singapore, 10903 New Hampshire Avenue, Under 21 CFR 201.303, specific warning language is required for drug preparations that contain significant proportions (5% or higher) of wintergreen oil. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192). Before sharing sensitive information, make sure you're on a federal government site. Find key decision-makers, contacts, emails, headcount, share capital, recent funding, IPO status and other insights of HAW PAR HEALTHCARE LIMITED. You failed to test the returned sample to confirm the amount of active ingredient in the product. Contact:Lu Mei Chu Tel: 65-0-63037336 Mail: lumeichu@hph.hawpar.com 3001432470. Tiger Balm is the world’s leading analgesic remedy that works where it hurts.This product is readily available in hundreds of countries, and it's suitable for athletes to housewife. After you receive this letter, respond to this office in writing within 15 working days. Our commercial and industrial properties in Singapore and Malaysia situated at prime locations make good corporate homes for tenants. The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Haw Par Healthcare Limited at 2 Chia Ping Road, #09-03, Haw Par TIGER BALM Building, Singapore, from February 25 to March 1, 2019. The company offers ethical pharmaceutical preparations, Tiger Balm, Kwan Loong Oil, Tiger Balm Kwan Loong Oil, Tiger Medicated Plaster and Tiger Muscle Rub. For example, degradation chromatographic peaks of less than (b)(4)% of the API were determined to be insignificant. Manufactured by Haw Par Healthcare Ltd., Singapore under licence from Haw Par Corporation Ltd. The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Haw Par Healthcare Limited at 2 Chia Ping Road, #09-03, Haw Par TIGER BALM Building, Singapore, from … Questions (510) 887-1899. In your response, you stated that you moved GC testing to other instruments with audit trail functionality, and you will update your FTIR and UV instrumentation with audit trails in 2020. Haw Par Corporation Limited, a Singapore-grown multinational Group, is listed on the Singapore Exchange since 1969. The labeler has 13 products that have an assigned National Drug Code. Call Us 03 9428 9982. 2. Even though all sub lots of drug product were made using API from a deficient mixing process, you only rejected portions of the drug product batches that were found to be OOS. 351(a)(2)(B). GET IN TOUCH! Haw Par Healthcare Ltd. labeler's code is 66761. In your response, you stated that you will “re-study your forced degradation approach,” complete a protocol that includes acceptance criteria, and establish test procedures with specifications for monitoring impurities. 401 Commonwealth Drive Its largest customer is Prince of Peace Enterprises INC (ca) with most shipments via the port of New York/ Newark Area, Newark, New Jersey. In addition, your practice of flushing the system at the manufacturing sampling points before sample collection for, analysis is not consistent with how you use these, points of use in production. Recalls, Market Withdrawals and Safety Alerts, Inspections, Compliance, Enforcement, and Criminal Investigations, Haw Par Healthcare Limited - 578581 - 08/19/2019, https://www.fda.gov/media/119267/download. This inconsistent sampling practice could potentially lead to inaccurate microbial results for, In your response, you stated that you have re-designed your, Your response is inadequate because you have not provided your data and evaluation of all. Find out what works well at Haw Par Healthcare Limited from the people who know best. Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. PRINCIPAL DISPLAY PANEL - 18 G Jar Box. HAW PAR HEALTHCARE LTD: Labor Productivity Benchmarks and International Gap … Find their customers, contact information, and details on 892 shipments. For example, degradation chromatographic peaks of less than, For example, the main peak area of your API. This warning letter summarizes significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals. Note: Files are in Adobe (PDF) format. Haw Par Corporation Limited \ Annual Report 2008 1 HAW PAR CORPORATION LIMITED has been listed on The Singapore Exchange since 1969. Therefore, the marketing of “TIGER BALM LINIMENT” violates this provision of the FD&C Act. Sector / Industry Group / Industry: Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals HAW PAR CORP LTD (H02.SI) General HAW PAR CORP LTD (H02.SI) Share Price Its top carrier is Eastrong International Logistic Company. Silver Spring, MD 20993 NDC 66761-333-22. Bond Fund of America - ‘N-30D’ for 6/30/98 Annual or Semi-Annual Report Mailed to Shareholders of an Investment Company - Seq. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance. HAW PAR HEALTHCARE LIMITED is a supplier in Singapore, Singapore. Haw Par Corporation Limited, a Singapore-grown multinational Group, is listed on the Singapore Exchange since 1969. The drug product specifications established for monitoring impurities. For example, the main peak area of your API (b)(4) for (b)(4) Patch decreased by approximately 12% after the oxidative degradation study, yet your chromatographic report did not include a record of impurities resulting from the API degradation. Name: Tiger Balm Red Extra Strength Form: ointment Ingredients: Camphor (Synthetic) 110mg in 1g, MENTHOL, UNSPECIFIED FORM 100mg in 1g Date: 2018-07-17 Labeler: Haw Par Healthcare Ltd. NDC … Your response is inadequate because your mixing study did not evaluate multiple batches from your suppliers to determine if your process can consistently achieve homogeneity with varying levels of raw material quality. system failures on the quality of all drug product lots currently in U.S. distribution and within expiry. It has exported 92.00002 shipments to the U.S. this year. Find the latest Haw Par (H02.SI) stock quote, history, news and other vital information to help you with your stock trading and investing. Haw Par Healthcare Limited operates as a subsidiary of Haw Par Corp. Ltd. Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. Links . In addition, your firm manufactures “TIGER BALM LINIMENT.” The product is misbranded under section 502(f)(2) of the FD&C Act, 21 U.S.C. aw Par Corporation Limited, a Singapore grown multinational Group, is listed on the Singapore Exchange since 1969. Note: Files are in Adobe (PDF) format. Nội dung của trang này chỉ nhằm mục đích thông tin. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)). First, it owns the iconic Tiger Balm brand, which is a recognised and. Haw Par has a long history of contributing to communities in regions where the company conducts business. Haw Par Healthcare Ltd. 659207039: MANUFACTURE(66761-354) View All Sections Close All Sections. You also invalidated an assay OOS result for, In your response, you acknowledge inadequate mixing of, For more information about handling failing, out-of-specification, out-of-trend, or other unexpected results and documentation of your investigations, see FDA’s guidance document. 331(a). Examples of claims observed on the product label that establish the intended uses, as defined in 21 CFR 201.128, of the product include, but may not be limited to, the following: “For temporary relief of minor aches and pains of muscles and joints associated with simple backache, arthritis, bruises, sprains and strains.”. 22k shipments total HAW (LP HACKLEBURG) VF JEANSWEAR LP HACKLEBURG HACKLEBURG DC, 3561 5 US HWY 43 HACKLEBURG AL 35564, US . Your response is inadequate because you have not provided your data and evaluation of all (b)(4) sampling points, with consistent sampling procedures, used for manufacturing to ensure that your microbial results comply with specifications. Haw Par aims to establish better communications with investors by providing our latest press releases, investors' events and financial statements announcement in this section. TIGER BALM PAIN RELIEVING HYDROGEL- camphor (synthetic), levomenthol, and capsicum patch Haw Par Healthcare Ltd. Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. Please download the free Adobe Acrobat Reader to view these documents. In your response, you acknowledge inadequate mixing of (b)(4) API led to the OOS drug product results. Common Stock, par value $0.10 per share (Title of Class of Securities) 075811109 (CUSIP Number of Class of Securities) Arnold A. Pinkston . Specifically, this product is intended as an external analgesic. The labeling of “TIGER BALM LINIMENT” fails to bear such warnings. Listed in 1969, Haw Par Corporation Ltd (Haw Par) derives income from two key businesses. TIGER BALM- camphor (synthetic), menthol, and capsicum patch Haw Par Healthcare Ltd. Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply … Find additional resources (also available in the left menu) Safety. A CAPA plan that identifies the potential manufacturing root causes for each such investigation and includes process improvements where appropriate. Your firm completed forced degradation studies for your OTC drug products but did not use the data to scientifically establish stability acceptance criteria. The .gov means it’s official.Federal government websites often end in .gov or .mil. In addition, there is no assurance that the analytical test methods that you used were capable of quantifying all drug product impurities resulting from the forced degradation studies you performed. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Legal information - Haw Par Healthcare Limited. 352(f)(2). Also include the validation protocol and report completed for these test methods.